Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques.

Golgi dysfunction has been previously investigated as a mechanism involved in monocrotaline-induced pulmonary hypertension (PAH). In the present study, we addressed whether Golgi dysfunction might occur in pulmonary vascular cells in idiopathic PAH (IPAH) and whether there might be a causal relationship between trafficking dysfunction and vasculopathies of PAH. Quantitative immunostaining for the Golgi tethers giantin and p115 on human lung tissue from patients with IPAH (n = 6) compared with controls demonstrated a marked cytoplasmic dispersal of giantin- and p115-bearing vesicular elements in vascular cells in the proliferative, obliterative, and plexiform lesions in IPAH and an increase in the amounts of these Golgi tethers/matrix proteins per cell. The causality question was approached by genetic means using human immunodeficiency virus (HIV)-Nef, a protein that disrupts endocytic and trans-Golgi trafficking. Macaques infected with a chimeric simian immunodeficiency virus (SIV) containing the HIV-nef gene (SHIV-nef), but not the nonchimeric SIV virus containing the endogenous SIV-nef gene, displayed pulmonary arterial vasculopathies similar to those in human IPAH. Giantin and p115 levels and their subcellular distribution in pulmonary vascular cells in lungs of SHIV-nef infected macaques (n = 4) were compared with SIV-infected (n = 3) and an uninfected macaque control. Only macaques infected with chimeric SHIV-nef showed pulmonary vascular lesions containing cells with dramatic cytoplasmic dispersal and an increase in giantin and p115. Specifically, the HIV-Nef-positive cells showed increased giantin, p115, and the activated transcription factor PY-STAT3. These data represent the first test of the Golgi dysfunction hypothesis in IPAH and place trafficking and Golgi disruption in the chain of causality of pulmonary vasculopathies in the macaque model.

[1]  P. Sehgal,et al.  Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[2]  P. Sehgal,et al.  Depletion of the ATPase NSF from Golgi membranes with hypo-S-nitrosylation of vasorelevant proteins in endothelial cells exposed to monocrotaline pyrrole. , 2008, American journal of physiology. Heart and circulatory physiology.

[3]  P. Sehgal,et al.  Cytoplasmic provenance of STAT3 and PY-STAT3 in the endolysosomal compartments in pulmonary arterial endothelial and smooth muscle cells: implications in pulmonary arterial hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[4]  H. Harada,et al.  Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. , 2008, Blood.

[5]  M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.

[6]  B. Gaston,et al.  S-nitrosothiols signal hypoxia-mimetic vascular pathology. , 2007, The Journal of clinical investigation.

[7]  F. Haddad,et al.  Management strategies for patients with pulmonary hypertension in the intensive care unit* , 2007, Critical care medicine.

[8]  Christine M. Miller,et al.  Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[9]  M. Corradi,et al.  Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. , 2007, Chest.

[10]  Jesse D. Roberts,et al.  Inhaled NO as a therapeutic agent. , 2007, Cardiovascular research.

[11]  P. Sehgal,et al.  Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. , 2007, American journal of respiratory cell and molecular biology.

[12]  P. Sehgal,et al.  Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs? , 2007, American journal of physiology. Heart and circulatory physiology.

[13]  P. Sehgal,et al.  Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[14]  R. Tuder,et al.  Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.

[15]  P. Sehgal,et al.  Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging. , 2007, American journal of physiology. Heart and circulatory physiology.

[16]  O. W. Lindwasser,et al.  Downregulation of CD4 by Human Immunodeficiency Virus Type 1 Nef Is Dependent on Clathrin and Involves Direct Interaction of Nef with the AP2 Clathrin Adaptor , 2007, Journal of Virology.

[17]  P. Luciw,et al.  HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. , 2006, American journal of respiratory and critical care medicine.

[18]  Allan Doctor,et al.  S-nitrosothiol signaling in respiratory biology. , 2006, American journal of respiratory and critical care medicine.

[19]  P. Sehgal,et al.  Discordant regulatory changes in monocrotaline-induced megalocytosis of lung arterial endothelial and alveolar epithelial cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[20]  D. Stewart,et al.  Role of angiopoietin-1 in experimental and human pulmonary arterial hypertension. , 2005, Chest.

[21]  G. Diette,et al.  Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. , 2005, American journal of respiratory and critical care medicine.

[22]  J. Yuan,et al.  Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. , 2005, Circulation.

[23]  Tracey M. Filzen,et al.  HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail , 2004, The Journal of cell biology.

[24]  J. Bonifacino,et al.  The Mechanisms of Vesicle Budding and Fusion , 2004, Cell.

[25]  G. Berry,et al.  Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells , 2003, Circulation.

[26]  J. Loyd,et al.  Primary pulmonary hypertension , 2003, The Lancet.

[27]  B. Dahlöf Response from Merck , 2003, The Lancet.

[28]  P. Thistlethwaite,et al.  Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.

[29]  K. Miyazono,et al.  Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. , 2002, Molecular biology of the cell.

[30]  N. Rudarakanchana,et al.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. , 2002, Human molecular genetics.

[31]  A. Roberts,et al.  Sorting Nexin 6, a Novel SNX, Interacts with the Transforming Growth Factor-β Family of Receptor Serine-Threonine Kinases* , 2001, The Journal of Biological Chemistry.

[32]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[33]  D. Olive,et al.  HIV-2 and SIV Nef Proteins Target Different Src Family SH3 Domains than Does HIV-1 Nef because of a Triple Amino Acid Substitution* , 2000, The Journal of Biological Chemistry.

[34]  P. Luciw,et al.  SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques. , 1999, Virology.

[35]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.